Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
18 studies found for:    weill | Open Studies | "Gastroenteritis"
Show Display Options
Rank Status Study
1 Not yet recruiting Triage Administration of Ondansetron for Gastroenteritis in Children
Condition: Gastroenteritis
Interventions: Drug: Ondansetron;   Drug: Placebos
2 Not yet recruiting Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Conditions: Crohn's Disease;   Spondyloarthritis
Intervention: Other: No intervention
3 Recruiting An Efficacy and Safety Study of Infliximab in Pediatric Participants With Inflammatory Bowel Disease
Condition: Inflammatory Bowel Diseases
Intervention: Drug: Infliximab
4 Recruiting A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
Intervention:
5 Recruiting Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: JNJ-64304500;   Drug: Placebo;   Drug: Ustekinumab
6 Recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Conditions: Colitis, Ulcerative;   Inflammatory Bowel Diseases
Interventions: Drug: Placebo IV;   Drug: Placebo SC;   Drug: Ustekinumab IV;   Drug: Ustekinumab SC
7 Recruiting A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Conditions: Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis;   Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab;   Drug: No Biologics
8 Recruiting Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Condition: Crohn Disease
Intervention: Drug: etrolizumab
9 Recruiting A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Etrolizumab 210 mg;   Drug: Etrolizumab 105 mg;   Drug: Placebo
10 Recruiting A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: GED-0301;   Other: Placebo
11 Recruiting Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: GED-0301;   Drug: Placebo
12 Recruiting Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Condition: Colitis, Ulcerative
Intervention: Drug: PF-06480605
13 Recruiting A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Mirikizumab;   Drug: Placebo
14 Recruiting Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: RPC1063
15 Recruiting Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: RPC1063;   Drug: Placebo
16 Recruiting A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: Etrozulimab;   Drug: Placebo
17 Recruiting A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Condition: Colitis, Ulcerative
Interventions: Drug: Etrolizumab;   Drug: Placebo
18 Recruiting Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
Condition: Ulcerative Colitis
Intervention: Drug: Etrolizumab

Study has passed its completion date and status has not been verified in more than two years.